We have been committed to R&D from day one in order to continue offering the latest technology in computational drug discovery services, and to discover new methods and algorithms for data processingin biomedical research.

Mind the Byte has collaboration agreements with the University of Barcelona, Autonomous University of Barcelona, Pompeu Fabra University and University of Vic - Central University of Catalonia. We are also active participants in European projects and consortia within the framework of Horizon 2020 and the earlier Seventh Framework Programme (7PM), both of which play key roles in accelerating innovation and converting it into real solutions for the unresolved problems of many diseases.

Translink (7PM)

Translink (2013-2017) is a project of the European Union Seventh Framework Programme that aims to determine the factors that lead to deterioration and failure in biological heart valve prostheses caused by an autoimmune response and to develop treatments to prevent these problems. Every year, some 400,000 people across the globe require a heart valve replacement.

As a company specializing in applied bioinformatics solutions for biotechnology and biomedical research, Mind the Byte's contribution to this project consists of the computational discovery and design (in silico) of new compounds that can take on antibodies related to prosthesis damage.


StemChem (COST Action)

Another European project we are working on is COST Action Chemical Approaches to TargetingDrug Resistance in Cancer Stem Cells (2012-2016), which brings together researchers with experience in drug discovery and in the medicinal chemistry of synthetic and natural compounds, and researchers who study the mechanisms that govern the drug resistance of stem cells in cancer.

Stem cells play a key role in the failure of current cancer therapies. This means a completely new approach to drug development is needed. Sharing the experience and knowledge of groups of experts in chemistry and biology could very well lead to the creation of effective methods to identify new compounds and candidate drugs to target drug-resistant cancerous stem cells. Mind the Byte participates in the computational models workgroup.


CM1407 (COST Action)

The COST Action Challenging Organic Syntheses Inspired by Nature from Natural Products Chemistry to Drug Discovery (2015-2019) seeks to make advances in the study of natural products (NP), which have had a significant impact on drug discovery and have been among the remedies used by physicians since ancient times. COST Action combines synthetic chemistry, computational chemistry, biological chemistry, and pharmacology to find new and relevant pharmaceutical structures for the treatment of cancer, cardiovascular disease, and bacterial and fungal infections.


Industrial doctorate programme

We are participating in the Government of Catalonia's Industrial Doctorate Programme in conjunction with the University of Vic-Central University of Catalonia, which promotes innovation and knowledge transfer between universities and the business world. Incorporating doctoral students into Mind the Byte's bioinformatics team has allowed us to conduct new research projects like, for example, the development of an extraordinarily innovative virtual screening method for the pharmaceutical sector.